Skip to main content
    R

    Rxsight Inc (RXST)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.83
    -0.47 (-8.87%)

    Market Cap: $223.06M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Rxsight Inc (RXST) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rxsight (RXST) has a market cap of $223.06M and an enterprise value of $164.82M. It kept -43.80% of revenue as net income over the last 12 months. It holds $58.24M more cash than debt, 26.11% of its market cap.

    Total Valuation

    Enterprise value is 26.11% below the market cap, as cash exceeds debt.

    Market Cap$223.06M
    Enterprise Value$164.82M
    Latest price (Nov 17, 2026)$4.83

    Key Dates

    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.52% in the quarter ended Sep 30, 2026 and grew 2.38% a year over 2 years.

    Shares Outstanding41.71M
    Shares Change (YoY)+1.81%
    Shares Change (QoQ)+0.52%
    Share Count Growth (2Y CAGR)+2.38%

    Valuation Ratios

    Sales and book value multiples are 1.7x and 0.8x. Its year-end P/S ranged from 3.2x to 15.7x from 2021 to 2025.

    P/S Ratio1.7x
    Forward P/S1.5x
    P/B Ratio0.8x
    P/FCF Ratio10.8x
    P/OCF Ratio9.4x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 7.7x free cash flow.

    EV / Sales1.4x
    EV / FCF7.7x

    Price Statistics

    The stock is down 50.36% over 52 weeks and trades 3.21% below its 50-day average.

    Beta (1Y)1.36
    52-Week Change-50.36%
    1-Month Change+2.99%
    3-Month Change-21.59%
    6-Month Change-18.82%
    5-Year Change-59.35%
    Total Return (1Y)-50.36%
    Total Return (3Y CAGR)-44.01%
    Total Return (5Y CAGR)-17.72%
    Return vs SPY (1Y)-61.25%
    Max Drawdown (1Y)-65.55%
    Max Drawdown (3Y)-92.98%
    Sharpe Ratio (1Y)-1.09
    Correlation with SPY (1Y)0.29
    50-Day Average$4.99
    200-Day Average$6.10
    52-Week Range$4.11 to $13.22
    RSI (14 Days)46.5
    Average Volume (20 Days)943.53K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.20x current liabilities, and total debt is 0.03x shareholder equity.

    Current Ratio4.20x
    Quick Ratio3.67x
    Debt / Equity0.03x
    Debt / FCF0.45x
    Interest Coverage-4727.15x

    Returns and Efficiency

    Return on invested capital is -23.33% over the last 12 months, against a 5-year average of -16.88%.

    Return on Equity (ROE)-20.93%
    Return on Assets (ROA)-15.67%
    Return on Invested Capital (ROIC)-23.33%
    ROE (5Y Average)-32.73%
    ROA (5Y Average)-23.49%
    ROIC (5Y Average)-16.88%
    Asset Turnover0.38x
    Inventory Turnover0.38x
    Receivables Turnover2.55x
    Cash Conversion Cycle972 days

    Scores

    RXST has an Altman Z-Score of -0.88, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-0.88
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $121.83M over the last 12 months is down 14.26% from the 12 months before.

    Revenue$121.83M
    Revenue Growth (YoY)-14.26%
    Gross Profit$107.09M
    Operating Income-$61.45M
    Pretax Income-$53.23M
    Net Income-$53.36M
    Reported EPS (TTM)-$0.90

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 74.88% of the $340.42M in total assets.

    Cash and Equivalents$66.72M
    Total Debt$8.48M
    Net Cash$58.24M
    Net Cash Per Share$1.40
    Working Capital$239.85M
    Shareholder Equity$254.91M
    Book Value Per Share$6.11
    Total Assets$340.42M
    Total Liabilities$85.51M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.03M of capital spending, operating cash flow left $18.64M of free cash flow.

    Operating Cash Flow$23.67M
    Capital Expenditures$5.03M
    Free Cash Flow$18.64M
    FCF Per Share$0.45
    Depreciation and Amortization$10.75M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -50.44%, against a 5-year average of -96.25%.

    Gross Margin87.90%
    Operating Margin-50.44%
    Pretax Margin-43.69%
    Net Margin-43.80%
    FCF Margin15.30%
    Gross Margin (5Y Average)54.24%
    Operating Margin (5Y Average)-96.25%
    Net Margin (5Y Average)-90.97%

    Growth

    Revenue grew 40.00% a year over 3 years.

    Revenue Growth (3Y CAGR)+40.00%
    Revenue Growth (5Y CAGR)+55.74%
    Book Value Per Share Growth (2Y CAGR)+22.53%
    Tangible Book Per Share Growth (2Y CAGR)+22.53%

    Revenue and profit by year

    Dividends and Yields

    RXST does not pay a dividend. Its free cash flow yield is 9.26%.

    FCF Yield9.26%
    Buyback Yield-1.04%
    Shareholder Yield-1.04%

    Peer Position

    Against 12 similar companies, RXST has the 9th highest P/S.

    P/S Ratio1.7x vs 2.9x median
    ROIC-23.33% vs -22.83% median
    Revenue Growth (Trailing 4 Quarters, YoY)-14.26% vs +5.60% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -7.24% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-7.24%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RXST

    What is RXST's market cap?

    Rxsight has a market cap of $223.06M. Its enterprise value, which adds debt and subtracts cash, is $164.82M.

    How many shares of RXST are outstanding?

    Rxsight has 41.71M shares outstanding. The count is up 1.81% from a year earlier.

    Does RXST pay a dividend?

    No. Rxsight does not pay a dividend.

    How much debt does RXST have?

    Rxsight has $8.48M of total debt and $66.72M of cash and equivalents, a net cash position of $58.24M.